BLUEBIRD BIO INC (BLUE) Stock News

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Bluebird Bio to Cut 25% of Staff Amid Gene Therapy Struggles

Bluebird Bio Inc. announced plans to cut about a quarter of its workforce as the biotech confronts a difficult environment for companies that make gene therapies, costly one-time treatments for hard-to-treat conditions.

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

bluebird bio Announces September Investor Events

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Interesting BLUE Call Options For October 18th

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Announces Second Quarter 2024 Results Call Date

CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Commit To Buy bluebird bio At $1, Earn 41.2% Annualized Using Options

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

/PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare...

bluebird bio Appoints O. James Sterling as Chief Financial Officer

BLUE FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action - BLUE

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.